-
Je něco špatně v tomto záznamu ?
Pulmonary Vein Isolation With Very High Power, Short Duration, Temperature-Controlled Lesions: The QDOT-FAST Trial
VY. Reddy, M. Grimaldi, T. De Potter, JM. Vijgen, A. Bulava, MF. Duytschaever, M. Martinek, A. Natale, S. Knecht, P. Neuzil, H. Pürerfellner,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu klinická studie, časopisecké články, multicentrická studie, práce podpořená grantem
- MeSH
- design vybavení MeSH
- fibrilace síní chirurgie MeSH
- fluoroskopie MeSH
- katetrizační ablace * škodlivé účinky přístrojové vybavení metody MeSH
- katétry škodlivé účinky MeSH
- léčebná irigace přístrojové vybavení MeSH
- lidé středního věku MeSH
- lidé MeSH
- mikroelektrody MeSH
- prospektivní studie MeSH
- senioři MeSH
- venae pulmonales chirurgie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinická studie MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
OBJECTIVES: This study sought to evaluate the safety and short-term performance of a novel catheter for very high power-short duration (vHPSD) ablation in the treatment of paroxysmal atrial fibrillation. BACKGROUND: The vHPSD catheter is a novel contact force-sensing catheter optimized for temperature-controlled radiofrequency ablation with microelectrodes and 6 thermocouples for real-time temperature monitoring; the associated vHPSD algorithm modulates power to maintain target temperature during 90 W, 4 s lesions. METHODS: QDOT-FAST (Clinical Study for Safety and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH SF-5D System Used With Fast Ablation Mode in Treatment of Patients With Paroxysmal Atrial Fibrillation) is a prospective, multicenter, single-arm study enrolling patients with symptomatic paroxysmal atrial fibrillation indicated for catheter-based pulmonary vein isolation. Primary endpoints were short-term effectiveness (confirmation of entrance block in all targeted pulmonary veins after adenosine/isoproterenol challenge) and short-term safety (primary adverse events). Participants were screened for silent cerebral lesions by magnetic resonance imaging. Patients were followed for 3 months post-ablation. RESULTS: A total of 52 patients underwent ablation and completed follow-up. Pulmonary vein isolation was achieved in all patients using the study catheter alone, with total procedure and fluoroscopy times of 105.2 ± 24.7 min and 6.6 ± 8.2 min, respectively. Most patients (n = 49; 94.2%) were in sinus rhythm at 3 months. Two primary adverse events were reported: 1 pseudoaneurysm; and 1 asymptomatic thromboembolism. There were no deaths, stroke, atrioesophageal fistula, pulmonary vein stenosis, or unanticipated adverse device effects. Six patients had identified silent cerebral lesions-all classified as asymptomatic without clinical or neurologic deficits. CONCLUSIONS: This first-in-human study of a novel catheter with optimized temperature control demonstrated the clinical feasibility and safety of vHPSD ablation. Procedure and fluoroscopy times were substantially lower than historical standard ablation with point-by-point catheters. (Clinical Study for Safety and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH SF-5D System Used With Fast Ablation Mode in Treatment of Patients With Paroxysmal Atrial Fibrillation [QDOT-FAST]; NCT03459196).
Cardiac Electrophysiology Icahn School of Medicine at Mount Sinai New York New York
Cardiovascular Center Onze Lieve Vrouwziekenhuis Hospital Aalst Belgium
Department of Cardiology Algemeen Ziekenhuis Sint Jan Bruges Belgium
Department of Cardiology Na Homolce Hospital Prague Czech Republic
Department of Cardiology Ordensklinikum Linz Elisabethinen Linz Austria
Department of Cardiology Ospedale Generale Regionale F Muilli Acquaviva delle Fonti Italy
Hasselt Heart Center Jessa Hospital Hasselt Belgium
Texas Cardiac Arrhythmia Institute St David's Medical Center Austin Texas
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028886
- 003
- CZ-PrNML
- 005
- 20210304151930.0
- 007
- ta
- 008
- 210105s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jacep.2019.04.009 $2 doi
- 035 __
- $a (PubMed)31320006
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Reddy, Vivek Y $u Cardiac Electrophysiology, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic. Electronic address: vivek.reddy@mountsinai.org.
- 245 10
- $a Pulmonary Vein Isolation With Very High Power, Short Duration, Temperature-Controlled Lesions: The QDOT-FAST Trial / $c VY. Reddy, M. Grimaldi, T. De Potter, JM. Vijgen, A. Bulava, MF. Duytschaever, M. Martinek, A. Natale, S. Knecht, P. Neuzil, H. Pürerfellner,
- 520 9_
- $a OBJECTIVES: This study sought to evaluate the safety and short-term performance of a novel catheter for very high power-short duration (vHPSD) ablation in the treatment of paroxysmal atrial fibrillation. BACKGROUND: The vHPSD catheter is a novel contact force-sensing catheter optimized for temperature-controlled radiofrequency ablation with microelectrodes and 6 thermocouples for real-time temperature monitoring; the associated vHPSD algorithm modulates power to maintain target temperature during 90 W, 4 s lesions. METHODS: QDOT-FAST (Clinical Study for Safety and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH SF-5D System Used With Fast Ablation Mode in Treatment of Patients With Paroxysmal Atrial Fibrillation) is a prospective, multicenter, single-arm study enrolling patients with symptomatic paroxysmal atrial fibrillation indicated for catheter-based pulmonary vein isolation. Primary endpoints were short-term effectiveness (confirmation of entrance block in all targeted pulmonary veins after adenosine/isoproterenol challenge) and short-term safety (primary adverse events). Participants were screened for silent cerebral lesions by magnetic resonance imaging. Patients were followed for 3 months post-ablation. RESULTS: A total of 52 patients underwent ablation and completed follow-up. Pulmonary vein isolation was achieved in all patients using the study catheter alone, with total procedure and fluoroscopy times of 105.2 ± 24.7 min and 6.6 ± 8.2 min, respectively. Most patients (n = 49; 94.2%) were in sinus rhythm at 3 months. Two primary adverse events were reported: 1 pseudoaneurysm; and 1 asymptomatic thromboembolism. There were no deaths, stroke, atrioesophageal fistula, pulmonary vein stenosis, or unanticipated adverse device effects. Six patients had identified silent cerebral lesions-all classified as asymptomatic without clinical or neurologic deficits. CONCLUSIONS: This first-in-human study of a novel catheter with optimized temperature control demonstrated the clinical feasibility and safety of vHPSD ablation. Procedure and fluoroscopy times were substantially lower than historical standard ablation with point-by-point catheters. (Clinical Study for Safety and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH SF-5D System Used With Fast Ablation Mode in Treatment of Patients With Paroxysmal Atrial Fibrillation [QDOT-FAST]; NCT03459196).
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a fibrilace síní $x chirurgie $7 D001281
- 650 12
- $a katetrizační ablace $x škodlivé účinky $x přístrojové vybavení $x metody $7 D017115
- 650 _2
- $a katétry $x škodlivé účinky $7 D057785
- 650 _2
- $a design vybavení $7 D004867
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fluoroskopie $7 D005471
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mikroelektrody $7 D008839
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a venae pulmonales $x chirurgie $7 D011667
- 650 _2
- $a léčebná irigace $x přístrojové vybavení $7 D007507
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a klinická studie $7 D000068397
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Grimaldi, Massimo $u Department of Cardiology, Ospedale Generale Regionale F. Muilli, Acquaviva delle Fonti, Italy.
- 700 1_
- $a De Potter, Tom $u Cardiovascular Center, Onze Lieve Vrouwziekenhuis, Hospital, Aalst, Belgium.
- 700 1_
- $a Vijgen, Johan M $u Hasselt Heart Center, Jessa Hospital, Hasselt, Belgium.
- 700 1_
- $a Bulava, Alan $u Department of Cardiology, Ceske Budejovice Hospital, Faculty of Health and Social Sciences, University of South Bohemia in Ceske Budejovice, Ceske Budejovice, Czech Republic.
- 700 1_
- $a Duytschaever, Mattias, $u Department of Cardiology, Algemeen Ziekenhuis Sint Jan, Bruges, Belgium. $d 1970- $7 xx0257832
- 700 1_
- $a Martinek, Martin $u Department of Cardiology, Ordensklinikum Linz Elisabethinen, Linz, Austria.
- 700 1_
- $a Natale, Andrea $u Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas.
- 700 1_
- $a Knecht, Sebastien $u Department of Cardiology, Algemeen Ziekenhuis Sint Jan, Bruges, Belgium.
- 700 1_
- $a Neuzil, Petr $u Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic.
- 700 1_
- $a Pürerfellner, Helmut $u Department of Cardiology, Ordensklinikum Linz Elisabethinen, Linz, Austria.
- 773 0_
- $w MED00193518 $t JACC. Clinical electrophysiology $x 2405-5018 $g Roč. 5, č. 7 (2019), s. 778-786
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31320006 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210304151844 $b ABA008
- 999 __
- $a ok $b bmc $g 1609221 $s 1120066
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 5 $c 7 $d 778-786 $e 20190508 $i 2405-5018 $m JACC. Clinical electrophysiology $n JACC Clin Electrophysiol $x MED00193518
- LZP __
- $a Pubmed-20210105